The ASCO-GU event rationale is to provide Italian urologists with the most recent scientific evidences regarding diagnosis and treatment of urologic malignancies. ASCO-GU represents a real special meeting owing to the attendance of the top international experts in uro-oncology. A key aspect of the meeting is its multidisciplinarity, that at present is considered a crucial point in uro-oncology. Clinical oncologists, radiotherapists, pathologists and urologists have discussed and presented all together the most recent pre-clinical and clinical studies conducted in the last year. The topics concerned: prostate cancer, bladder and upper urinary tract cancer, kidney cancer. Three Italian experts particularly involved in uro-oncology attended ASCO-GU 2019 held in San Francisco. Renzo Colombo (bladder and upper urinary tract cancer specialist), Alessandro Sciarra (prostate cancer specialist), and prof. Carlo Terrone (kidney cancer specialist) attended in particular the specific programs in the different oncological areas and they will present to Italian urologists not only the most relevant news and innovations emerging from the US meeting but also the evidences they consider have the possibility to change the everyday clinical practice in urology.

Kidney Cancer

COORDINATOR:

TEAM:

UMBERTO CAPITANIO, ANDREA MINERVINI, ALESSANDRA MOSCA, CAMILLO PORTA

Bladder Cancer

COORDINATOR: RENZO COLOMBO

TEAM: ROBERTO BORDONARO, ANDREA NECCHI, VINCENZO SERRETTA, NAZARENO SUARDI

Prostate Cancer

COORDINATOR: ALESSANDRO SCIARRA

TEAM: LORENZO ANTONUZZO, PASQUALE DITONNO, ANTONIO GALFANO, STEFANO SALCICCIA

SUPPORTED BY A NON CONDITIONAL EDUCATIONAL GRANT OF:





CHAIRMAN Prof. Giuseppe Carrieri







MAY 16th, 2019 ROMA

BEST WESTERN PREMIER HOTEL ROYAL SANTINA Via Marsala, 22

PROGRAMME

11.00 - 12.30 **Kidney Cancer**

COORDINATOR: CARLO TERRONE

TEAM: UMBERTO CAPITANIO, ANDREA MINERVINI, ALESSANDRA MOSCA, CAMILLO PORTA

11.00 HIGHLIGHTS

11.15 DISCUSSION

11.30 ORAL COMMUNICATIONS AND POSTERS

11.45 DISCUSSION 12.00 UROLOGY AND CLINICAL PRACTICE CHANGES

12.15 DISCUSSION

12.30 - 14.00 **Bladder Cancer** COORDINATOR: RENZO COLOMBO

TEAM: ROBERTO BORDONARO, ANDREA NECCHI, VINCENZO SERRETTA, NAZARENO SUARDI

12.30 HIGHLIGHTS

12.45 DISCUSSION

13.00 ORAL COMMUNICATIONS AND POSTERS 13.15 DISCUSSION 13.30 UROLOGY AND CLINICAL PRACTICE

CHANGES 13.45 DISCUSSION

14.00 LUNCH COORDINATOR: ALESSANDRO SCIARRA TEAM: LORENZO ANTONUZZO, PASQUALE DITONNO, ANTONIO GALFANO, STEFANO SALCICCIA 15.00 HIGHLIGHTS 15.15 DISCUSSION

15.30 ORAL COMMUNICATIONS AND POSTERS

15.00-16.30 Prostate Cancer

15.45 DISCUSSION

16.00 CHANGES

16.15 DISCUSSION

16.30 CONCLUSIONS

17.00 ECM QUIZ

17.00 WORK END





UROLOGY AND CLINICAL PRACTICE

LEARNING OBJECTIVES Guidelines, Protocols, Procedures

ECM CREDITS The congress designates this activity for a maximum of 5 ECM CREDITS for Urologists.





ASCO GU ASCO GENITOURINARY CANCER SYMPOSIUM

HIGH-LIGHTS





ASCO GU ASCO GENITOURINARY CANCER SYMPOSIUM

MAY 16⁺, 2019 ROMA

Kidney Cancer

11.00 Introduction **C.TERRONE**

11.06 Treatment of localized renal cell carcinoma: the importance of renal function **A. MINERVINI**

11.22 Does cytoreductive nephrectomy still play a role? **U. CAPITANIO**

11.38 Discussion

11.48 Update on systemic treatment of metastatic RCC (I). **C. PORTA**

12.04 Update on systemic treatment of metastatic RCC (II). **A. MOSCA**

12.20 Discussion

Bladder Cancer

12.30 Introduction and hot points from ASCO-GU 2019 **R. COLOMBO**

12.35 Pure-1 and other clinical trials in the neo-adjuvant settings **A. NECCHI**

12.50

Clinical trials on chemo/immunotherapy for locally advanced and metastatic stages in mono and combination settings **R. BORDONARO**

13.05

Genomics, Biomarkers and novelties in non-muscle invasive bladder cancer **V. SERRETTA**

13.20

Radical cystectomy/ multimodal conservative approach and radiotherapy alone and in combination treatment studies

N. SUARDI

13.35

Round Table. News from ASCO-GU: from the stage to the clinical practice **R. COLOMBO**

Prostate Cancer

15.00 Introduction **A. SCIARRA**

15.05

Genomic and mMR in the initial diagnosis and prognostic evaluation **S. SALCICCIA**

15.20

Staging and primary treatments in M0 PC P. DI TONNO

15.35

DISCUSSION: which trials will change our clinical practice and Guidelines

15.50

- Oligometastatic PC and M0-CRPC A. GALFANO

16.05

Systemic treatments in mHSPC and CRPC LANTONUZZO

16.20

DISCUSSION: which trials will change our clinical practice and Guidelines

